Lupin's ANDA for Fosaprepitant Dimeglumine Receives AP Status from FDA
The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for Lupin's Fosaprepitant Dimeglumine.
Asset / Drug
Drug and asset intelligence for Fosaprepitant Dimeglumine with 3 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.